Exon skipping for Duchenne muscular dystrophy: a systematic review and meta-analysis

Abstract Background Exon skipping has been considered a promising therapeutic approach for Duchenne muscular dystrophy (DMD). Eteplirsen received conditional approval in the United States in 2016. To date, no systematic reviews or meta-analyses of randomized controlled trials (RCTs) of exon skipping...

Volledige beschrijving

Bibliografische gegevens
Hoofdauteurs: Yuko Shimizu-Motohashi, Terumi Murakami, En Kimura, Hirofumi Komaki, Norio Watanabe
Formaat: Artikel
Taal:English
Gepubliceerd in: BMC 2018-06-01
Reeks:Orphanet Journal of Rare Diseases
Onderwerpen:
Online toegang:http://link.springer.com/article/10.1186/s13023-018-0834-2